Benuvia Operations, LLC.
Jim Mitchell has over 20 years of experience in the field of organic chemistry and pharmaceutical research. Jim has held various roles, including Vice President of API Research and Development at Benuvia Manufacturing, where they specialize in cannabinoid chemistry and process optimization. Prior to this, they worked as a Senior R&D/Process Development Chemist at Insys Therapeutics, Inc., where they developed new GMP industrial platforms for cannabinoid synthesis and supported other company projects through organic synthesis and process optimization. Jim also has experience as a Research Scientist at Worldwide Clinical Trials, Inc., where they conducted protein characterization assays, and as a Scientist/Project Director at World Wide Clinical Trials, where they managed bioanalytical studies for the pharmaceutical industry. Jim began their career as a Graduate Research Assistant at the University of Hawaii at Manoa and also worked as a Synthesis Chemist at Cerilliant Corporation and an Analytical Chemist at McNeil Consumer Healthcare. Throughout their career, Jim has demonstrated expertise in multi-step organic synthesis, process optimization, and regulatory compliance.
Jim Mitchell attended The University of Texas at Austin from 1994 to 1999, where they obtained a Bachelor of Science degree in Organic Chemistry. Jim then pursued further education at the University of Hawaii at Manoa from 2003 to 2007, studying Organic Synthesis/Natural Products.
Benuvia Operations, LLC.
Benuvia Manufacturing is a leading developer and manufacturer of high-purity, pharmaceutical cannabinoid ingredients and products. We offer a comprehensive suite of solutions for pharmaceutical, biotechnology, and consumer product companies to achieve their development and commercial needs. We have over 100,000 square feet of state-of-the-art research, development and manufacturing space across two cGMP facilities in Chandler, Arizona and Round Rock, Texas. We began manufacturing pharmaceutical grade cGMP pure quality cannabidiol (CBD) in 2009 and our Round Rock facility has produced CBD since 2014 (DMF 32552). Today, Round Rock is the only CBD active pharmaceutical ingredient (API) contract manufacturing site in the U.S. producing an FDA approved cannabinoid drug (SYNDROS®). Our facilities are DEA and FDA registered cGMP production sites and are fully regulated and compliant with all DEA, EPA, and OSHA requirements. Further information is available at www.benuviamanufacturing.com.